The use of the diabetes drug pioglitazone for more than 1 year may be associated with an increased risk of bladder cancer, the US Food and Drug Administration (FDA) warned on June 15.
The FDA is advising health care professionals to not use pioglitazone in patients with active bladder cancer and to prescribe the drug with caution for patients with a prior history of bladder cancer, weighing the benefits of blood glucose control “against the unknown risks for cancer recurrence” (http://tinyurl.com/3owghao).
Stephenson J. Diabetes Drug May Be Associated With Increase in Risk of Bladder Cancer. JAMA. 2011;306(2):143. doi:10.1001/jama.2011.939